Table 3.
Association Between Orthostatic Hypotension at Baseline and Clinical Outcomes
| Outcome | No. of Events | Unadjusted Hazard Ratio (95% CI) (n = 3,873) | Adjusted Hazard Ratio (95% CI)a (n = 3,573) |
|---|---|---|---|
| Composite cardiovascular outcome | No OH = 875, OH = 65 | 1.74 (1.45-2.09) | 1.12 (1.03-1.21) |
| Kidney outcome | No OH = 1,074, OH = 90 | 1.85 (1.56-2.18) | 1.08 (0.9-1.3) |
| All-cause mortality | No OH = 770, OH = 49 | 1.39 (0.78-1.79) | 0.87 (0.64-1.14) |
| Heart failure | No OH = 447, OH = 31 | 1.63 (1.33-1.99) | 1.16 (0.92-1.43) |
| Myocardial infarction | No OH = 212, OH = 12 | 1.49 (1.21-1.84) | 1.15 (1.04-1.27) |
| Stroke | No OH = 126, OH = 6 | 1.46 (1.18-1.81) | 1.13 (1.02-1.25) |
| Peripheral arterial disease | No OH = 156, OH = 13 | 1.58 (1.28-1.95) | 1.13 (1.02-1.24) |
Note: Cardiovascular composite outcome includes heart failure, myocardial infarction, stroke and peripheral arterial disease. Kidney outcomes includes end-stage kidney disease or 50% decline in eGFR.
Abbreviations: eGFR, estimated glomerular filtration rate; OH, orthostatic hypotension.
Cox proportional hazards models adjusted for clinical center, age, sex, race, diabetes, seated systolic blood pressure, cardiovascular disease, smoking status, body mass index, ankle-brachial index, β-blocker use, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, eGFR, total cholesterol level, hemoglobin level, calcium level, phosphate level, and urinary albumin-creatinine ratio.